Sanofiand Regeneron Pharmaceuticals Inc.may be blazing a trail in the US with their approach to pricing their newly-approved biologic for atopic dermatitis, Dupixent (dupilumab).
The companies will launch the drug at a wholesale acquisition cost of $37,000, a price that many analysts believe is reasonable, and is even lower than some expected, given the drug's first-in-class status and the unmet need for an effective treatment